Fc proteins are the proteins which are found on the surface of various cells including B.lymphocytes, natural killer cells, follicular dendritic cells, neutrophils, basophils, macrophages, eosinophils and mast cells. Fc proteins help these cells in providing protective functions to the immune system by binding with antibodies at fragment crystallizable region. Fc proteins bind with antibodies that are connected with either invading pathogens or infected cells stimulating the cytotoxic and phagocytic cells to destroy microbes, or antibody-dependent cell-mediated cytotoxicity and antibody-mediated phagocytosis. Based on these mechanisms many research institutes and market players in pharmaceutical industries are involved in developing engineered antibodies based on Fc proteins mechanism. On the basis of the available drugs in phase II and phase III pipeline, Fc proteins engineered antibodies market can be segmented into three types which are as follows:
Ocaratuzumab (AME-133V) is a humanized monoclonal antibody aimed for the treatment of cancer and auto immune disorders. This drug is developed by Mentrik Biotech, LLC and is currently under phase III clinical trials. Phase I and II trials which were aimed on relapsed/refractory follicular lymphoma patients and rheumatoid arthritis patients in the U.S. and Japan respectively showed that ocaratuzumab is having 13 to 20 fold greater affinity then already available treatment drugs especially rituximab. Therefore, it is expected that this drug will prove beneficial in future assisting the growth of Fc proteins engineered antibodies market during the forecast period.
Margetuximab (MGAH22), Fc protein engineered antibody developed by Macrogeics, Inc. is currently under phase II clinical trials. This drug is designed to fight against advanced solid tumors expressing the HER2 oncoprotein. XmAB5574 (MOR208) is a Fc protein engineered monoclonal antibody in phase II development. The drug was developed by Xencor, Inc. and currently MacrphoSys AG is performing phase II clinical trials for the drug. The trials are aimed on treatment for B-cell acute lymphoblastic leukemia (B-ALL) and non-hodgkin lymphoma (NHL). Xencor, Inc. discovered XmAB5574 and licensed the exclusive worldwide right for all type of indications to MorphoSys Ag in 2010.
Fc proteins and glycoengineered antibodies market will grow rapidly aided by the major developments taking place in glycoengineered antibodies technology platform. There are various technologies such as GlycoMab technology, GlycoExpress technology and GlymaxX technology which could be utilized for the production of novel Fc proteins engineered antibodies. Moreover, Fc protein engineered antibodies also have other emerging opportunities in addition to oncology and immunology. For instance, companies with successful antibody drugs nearing patent expiry can develop Fc proteins engineered antibody using monoclonal antibody.
Additionally, the increasing prevalence of the cancer worldwide is encouraging the scientist in developing more effective cancer treatment methods. According to World Health Organization (WHO), cancer was the leading cause of death in 2012, accounting for 8.2 million deaths worldwide. High prevalence of cancer coupled with high mortality rate is demanding for new and novel cancer treatment methods, hence driving the Fc proteins engineered antibodies market. However, the market is likely to face competition from other innovative antibodies based therapeutic technologies and other glycoengineered antibodies, which will restrain the market. For example, two highly efficient antibody drug conjugates namely adcentris by Seattle Genetics, Inc. and kadcyla by Genentech, Inc. are already present in the market, which will hamper the easy entry of Fc protein engineered antibodies during the forecast period.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.